Skip to main content
Clinical Trials/NCT07364331
NCT07364331
Recruiting
Not Applicable

Omega- 3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder With (OMNeADHD) A Double Blind Randomized Controlled Trial of High Dose Omega- 3 Fatty Acids in Children and Adolescents With ADHD With Omega- 3 Deficiency.

China Medical University Hospital1 site in 1 country100 target enrollmentStarted: September 4, 2021Last updated:
InterventionsOmega-3Placebo

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
100
Locations
1
Primary Endpoint
Clinical symptoms-attention and impulsivity symptom severity

Overview

Brief Summary

This is a 12 week randomized controlled study on the effects of omega-3 fatty acids in youth with attention deficit hyperactivity disorder (ADHD) with omega-3 deficiency.

Detailed Description

This is a 12 week randomized controlled study on the effects of omega-3 fatty acids (EPA or DHA) in youth with attention deficit hyperactivity disorder (ADHD) with omega-3 deficiency.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description

double blind

Eligibility Criteria

Ages
6 Years to 18 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • DSM-5 diagnosis of ADHD
  • Did not have any changes of ADHD treatment (pharmacological/psychological) within 4 weeks of entering the trial.
  • SNAP-IV inattention subscale \>=12, or hyperactivity subscale \>=12, or inattention+ hyperactivity subscales \>=24

Exclusion Criteria

  • Allergic to omega-3
  • Physical disorders: thyroid function, cancer
  • Psychiatric comorbidity: SUD, psychotic disorders, bipolar disorder, major depressive disorder

Arms & Interventions

omega-3 fatty acids: EPA

Active Comparator

EPA

Intervention: Omega-3 (Dietary Supplement)

omega-3 fatty acids: DHA

Active Comparator

DHA

Intervention: Omega-3 (Dietary Supplement)

placebo

Placebo Comparator

olive oil

Intervention: Placebo (Dietary Supplement)

Outcomes

Primary Outcomes

Clinical symptoms-attention and impulsivity symptom severity

Time Frame: week 0,1,2,4,8,12

The Swanson, Nolan, and Pelham Rating Scale- 4th edition (SNAP-IV) is used to help assess symptoms of ADHD (Attention Deficit Hyperactivity Disorder) in children and adolescents. It consists of a series of questions that rate the severity of behaviors such as inattention, hyperactivity, and impulsivity, based on teacher and parent observations. The scale includes both parent and teacher versions, allowing for a comprehensive view of a child's behavior in different environments. The scoring system rates each behavior on a 4-point scale from 0 (never or rarely) to 3 (very often), and higher total scores indicate more significant ADHD symptoms. The results help clinicians in diagnosing ADHD and monitoring treatment progress.

Secondary Outcomes

  • Measurement of cognitive function: attention and impulsivity(week 0,12)
  • Concentration of Peripheral cortisol levels(week 0,12)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Pei-Chen Chang

Director of Child Psychiatry Division

China Medical University Hospital

Study Sites (1)

Loading locations...

Similar Trials